Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00120835 · ClinicalTrials.gov registry record · Phase 1
Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00120835: Completed Phase 1 study, sponsored by Merck Sharp & Dohme.
NCT00120835 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00120835, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
This study is being conducted in treatment-naive patients (no previous hepatitis C treatment) to evaluate the safety of valopicitabine (NM283) alone and together with pegylated interferon, a drug approved by the Food and Drug Administration for the treatment of hepatitis C infection. This study is also evaluating the ability of valopicitabine to decrease the amount of hepatitis C virus in the body. The results for patients taking valopicitabine alone will be compared with the results for patients taking valopicitabine together with pegylated interferon.
Interventions
- DRUG valopicitabine
- DRUG pegylated interferon
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-07 |
| Phase | Phase 1 |
What the finished NCT00120835 record still lists
NCT00120835 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which valopicitabine is the first listed.
NCT00120835 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00120835 about?
NCT00120835 is a clinical study titled "Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C". This study is being conducted in treatment-naive patients (no previous hepatitis C treatment) to evaluate the safety of valopicitabine (NM283) alone and together with pegylated interferon, a drug approved by the Food and Drug Administration for the treatment of hepatitis C infection. This study is a...
What is the current status of trial NCT00120835?
This trial is currently completed. It is a Phase 1 study. The study started on 2004-07.
What interventions are being tested in trial NCT00120835?
The interventions under investigation include: valopicitabine (DRUG), pegylated interferon (DRUG).
Who is sponsoring clinical trial NCT00120835?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia